Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Upgraded by Zacks Research

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. Piper Sandler restated an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday. Jefferies Financial Group raised Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their price target for the company from $1.80 to $3.00 in a research note on Thursday. Weiss Ratings upgraded Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Stock Up 16.9%

Shares of INO opened at $0.90 on Wednesday. The stock’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $1.30. The firm has a market capitalization of $74.05 million, a PE ratio of -0.99 and a beta of 1.52. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Analysts anticipate that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

A number of large investors have recently made changes to their positions in INO. Focus Partners Wealth acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Inovio Pharmaceuticals by 752.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 18,160 shares in the last quarter. Raymond James Financial Inc. increased its holdings in shares of Inovio Pharmaceuticals by 4,396.0% in the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 16,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth about $41,000. Institutional investors own 26.79% of the company’s stock.

Key Stories Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: INO-3107 regulatory progress: The FDA’s review of Inovio’s biologics license application for recurrent respiratory papillomatosis is advancing toward an October 30, 2026 PDUFA decision date. The company is also preparing commercially for a potential launch, an important catalyst for the development-stage biotech. INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Smaller-than-expected loss: Inovio reported a second-quarter loss of $0.07 per share, substantially better than the $0.22 loss analysts expected. The narrower loss supports the near-term investment case, although the company remains unprofitable. Inovio Second-Quarter Earnings Results
• Positive Sentiment: Improved funding visibility: Management said its cash, cash equivalents, and short-term investments are expected to fund operations through late first quarter 2027, potentially covering the period through an INO-3107 launch if approved and reducing immediate financing pressure. Inovio Q2 2026 Earnings Call Highlights
• Positive Sentiment: Pipeline developments: Partner ApolloBio reported positive topline Phase 3 results for VGX-3100 in cervical dysplasia, while Inovio also highlighted progress in its DNA-encoded antibody and protein programs. Inovio Second-Quarter 2026 Financial Results
• Negative Sentiment: Key risks remain: INO-3107 still requires FDA approval, and the company continues to report losses. Any regulatory delay, rejection, weaker launch prospects, or future need for additional capital could pressure INO. Inovio Q2 2026 Earnings Call Transcript

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.